Amendments to the Claims

The following Listing of Claims will replace all prior versions and listings of claims in the above-referenced application.

Listing of Claims:

Claims 1-15. (Canceled)

16. (Currently amended) A pharmaceutical composition for delivering a therapeutically effective amount of an epothilone ~~macrolide~~ to a mammal, the pharmaceutical composition comprising:

an amount of an epothilone ~~macrolide~~, wherein the epothilone comprises a 16-membered ring with an epoxide at C12-C13; and

a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols,

wherein the amount of the epothilone ~~macrolide~~ in the carrier is sufficient for the composition to deliver to the mammal between about 0.001 mg and about 0.6 mg of the epothilone ~~macrolide~~ per kg body weight.

17. (Currently amended) The pharmaceutical composition of claim 16, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.01 mg to about 0.6 mg of the epothilone ~~macrolide~~ per kg body weight.

18. (Previously presented) The composition of claim 16, wherein the composition is formulated for parenteral delivery.

19. (Previously presented) The composition of claim 16, wherein the composition is formulated for oral delivery.

20. (Previously presented) The composition of claim 16, wherein the composition comprises an emulsion.

21. (Previously presented) The composition of claim 16, wherein the composition comprises an aqueous suspension.

22. (Currently amended) A method of treating cancer in a subject comprising:

administering to the subject in need thereof an average daily dose of an epothilone ~~macrolide~~, wherein the epothilone comprises a 16-membered ring with an epoxide at C12-C13; and

a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols,

wherein the amount of the epothilone ~~macrolide~~ in the carrier is sufficient for the composition to deliver to the subject between about 0.001 mg and about 0.6 mg of the epothilone ~~macrolide~~ per kilogram of the subject's body weight.

23. (Currently amended) The method of claim 22, wherein the average daily dose is within the range of about 0.01 mg to about 0.6 mg of the epothilone ~~macrolide~~ per kg body weight.

24. (Previously presented) The method of claim 22, wherein the step of administering comprises administering individual doses not more frequently than once daily.

25. (Previously presented) The method of claim 22, wherein the step of administering comprises interrupting individual dose administrations with at least one day of rest.

26. (Previously presented) The method of claim 22, wherein the step of administering comprises interrupting individual dose administrations with at least three days of rest.

27. (Previously presented) The method of claim 22, wherein the step of administering comprises administering over a period of at least about 6 days.

28. (Previously presented) The method of claim 22, wherein the step of administering comprises administering to an animal that has a multidrug resistant tumor.

29. (Previously presented) The method of claim 22, wherein the step of administering according to a schedule sufficient to achieve at least about 16% tumor inhibition.